

Isturisa[®] (osilodrostat) – Expanded indication

- On April 16, 2025, [Recordati announced](#) the FDA approval of [Isturisa \(osilodrostat\)](#), for the **treatment of endogenous hypercortisolemia in adults with Cushing's syndrome** for whom surgery is not an option or has not been curative.
 - Isturisa was previously approved for adult patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative.
- The recommended initial dose of Isturisa is 2 mg orally twice daily. The maintenance dosage is individualized and determined by titration based on cortisol levels and patient's signs and symptoms.
 - The maintenance dosage varied between 2 mg and 7 mg twice daily in clinical trials.
 - The maximum recommended maintenance dosage of Isturisa is 30 mg twice daily.